Back to News
Market Impact: 0.35
Amgen Falls 10% as Novartis Trial Failure Clouds a Cholesterol Drug Class; NVS Stock Drops 14%
Source: 247wallst.com
Healthcare & BiotechCompany FundamentalsInvestor Sentiment & Positioning
Novartis' failed cholesterol trial is pressuring the Lp(a) drug-development class in Tuesday trading, with Amgen hit harder than other large-cap peers. The result raises investor concerns over the clinical and commercial outlook for Lp(a)-targeting therapies.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately negative
Sentiment Score
-0.45
Ticker Sentiment
AMGN-0.55
NVS-0.75
More News
- Newamsterdam Pharma stock hits 52-week low at 19.57 USD
- Voyager: Maintaining A Strong Buy For Q4 PET Imaging Data AD And More
- Next week brings major risks for the stock market, just as the AI trade keeps faltering
- AI Doubts Spread Cracks in Equities, Credit Markets: Evening Briefing Americas
- Kinder Morgan, Energy Transfer and Williams could benefit from cheap natural gas
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30